Analyst Price Targets — DTIL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 9, 2026 10:52 am | — | Oppenheimer | $20.00 | $6.77 | TheFly | Precision BioSciences initiated with an Outperform at Oppenheimer |
| March 13, 2026 6:57 pm | Maury Raycroft | Jefferies | $19.00 | $5.67 | StreetInsider | Precision BioSciences Inc. (DTIL) PT Lowered to $19 at Jefferies, but 'near-term setup is attractive' |
| April 1, 2024 7:19 am | Justin Zelin | BTIG | $30.00 | $13.56 | TheFly | Precision BioSciences price target raised to $30 from $2 at BTIG |
| November 10, 2022 10:11 am | — | Goldman Sachs | $1.00 | $1.38 | Benzinga | Goldman Sachs Maintains Neutral on Precision BioSciences, Lowers Price Target to $1 |
Latest News for DTIL
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD).…
PBGENE-HBV's liver biopsy data provides unusually direct evidence that ARCUS is editing the viral reservoir in patients. Durable off-treatment viral control remains unproven, making the next ELIMINATE-B updates decisive for the investment thesis. PBGENE-DMD offers a second validation path. However, their program still lacks disclosed human safety or efficacy data.
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUSÂ platform to develop in vivo gene editi
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a business update. “The second quarter marked a defining moment for Precision BioSciences and…
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the second quarter 2026 and provide a business update on Thursday, August 6, 2026. About Precision BioSciences, Inc. Precision…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DTIL.
U.S. House Trading
No House trades found for DTIL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.